St Phi Therapeutics
Shanghai
About St Phi Therapeutics
Yizun Biotechnology is a cutting-edge immune cell therapy company that has developed many unique platform technologies, including solid tumor treatment and allogeneic universal cell therapy.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $13.8M
- Funding stage: Early Stage Venture
- Last round: Series A (Apr 2024)
- Website: stphitherapeutics.com
- Phone: 7364541699
Industries & Categories
Biotechnology, Hospital, Medical
Canonical: https://fsome.com/organization/st-phi-therapeutics-74406 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.